(NASDAQ: NKTR) Nektar Therapeutics's forecast annual revenue growth rate of 54.89% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.23%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.39%.
Nektar Therapeutics's revenue in 2026 is $12,037,000.On average, 12 Wall Street analysts forecast NKTR's revenue for 2026 to be $1,210,574,663, with the lowest NKTR revenue forecast at $674,740,890, and the highest NKTR revenue forecast at $1,367,268,317. On average, 12 Wall Street analysts forecast NKTR's revenue for 2027 to be $1,051,069,588, with the lowest NKTR revenue forecast at $227,725,050, and the highest NKTR revenue forecast at $1,398,394,756.
In 2028, NKTR is forecast to generate $1,368,616,651 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $3,604,068,792.